Category: COVID-19 Complications, Co-infections, and Clinical Outcomes

Poster Session: COVID-19 Complications, Co-infections, and Clinical Outcomes

372 - Comparing the Outcome of COVID-19 in Cancer and Non-Cancer Patients: an International Multicenter Study

The ePoster content is available to users who are logged in.<br><br>Please log in and then come back here to use this button.

Presenting Author(s)

Ray Y. Hachem

Professor
MD Anderson UT
Houston, Texas
Disclosure: I do not have any relevant financial / non-financial relationships with any proprietary interests.

Co-Author(s)

TD

Tarcila Datoguia

Professor
Hospital Israelita Albert Einstein
Sao Paulo, Sao Paulo, Brazil
Disclosure: I do not have any relevant financial / non-financial relationships with any proprietary interests.
BS

Bilal Siddiqui

Medical Oncologist
Communty Health Network
Indiannapolis, Indiana
Disclosure: I do not have any relevant financial / non-financial relationships with any proprietary interests.
AF

Ana Fernandez Cruz

Professor
Hospital Universitario Puerta de Hierro
Madrid, Madrid, Spain
Disclosure: I do not have any relevant financial / non-financial relationships with any proprietary interests.
NM

Nobuyoshi Mori

Professor
St. Luke's International Hospital
Tokyo, Tokyo, Japan
Disclosure: I do not have any relevant financial / non-financial relationships with any proprietary interests.
SF

Suha Fakhreddine

Professor
Rafik Hariri University Hospital
Beirut, Beqaa, Lebanon
Disclosure: I do not have any relevant financial / non-financial relationships with any proprietary interests.
DL

Dong-Gun Lee

Professor
The Catholic University of Korea, Seoul, South Korea
Seoul, Seoul-t'ukpyolsi, Republic of Korea
Disclosure: I do not have any relevant financial / non-financial relationships with any proprietary interests.
EG

Edward Gorak

Professor
Baptist MD Anderson Cancer Center
Jacksonville, Florida
Disclosure: I do not have any relevant financial / non-financial relationships with any proprietary interests.
RS

Robert Somer

Professor
Cooper University Healthcare
Camden, New Jersey
Disclosure: I do not have any relevant financial / non-financial relationships with any proprietary interests.
AB

Arvinder Bhinder

Professor
OhioHealth Physician Group
Marion, Ohio
Disclosure: I do not have any relevant financial / non-financial relationships with any proprietary interests.
SS

Samuel Shelanski

Professor
Banner MD Anderson at Mckee Medical Center
Loveland, Colorado
Disclosure: I do not have any relevant financial / non-financial relationships with any proprietary interests.
TD

Tomislav Dragivich

Professor
Banner Health
Gilbert, Arizona
Disclosure: I do not have any relevant financial / non-financial relationships with any proprietary interests.
AB

Arnaud Bayle

Professor
Gustave Roussy Cancer Hospital
Villejuif, Lorraine, France
Disclosure: I do not have any relevant financial / non-financial relationships with any proprietary interests.
Roy F. Chemaly

Professor
MD Anderson
Houston, Texas
Disclosure: Chimerix (Consultant, Research Grant or Support)Clinigen (Consultant)Merck (Consultant, Research Grant or Support)Novartis (Research Grant or Support)Oxford Immunotec (Consultant, Research Grant or Support)Shire/Takeda (Research Grant or Support)Viracor (Research Grant or Support)
VM

Victor Mulonovich

Professor
UT MD Anderson Cancer Center
Houston, Texas
Disclosure: I do not have any relevant financial / non-financial relationships with any proprietary interests.
JA

Javier Adachi

Professor
MD Anderson Cancer Center
Houston, Texas
Disclosure: I do not have any relevant financial / non-financial relationships with any proprietary interests.
Alexandre Malek

Onco-Transplant Infectious Diseases Fellow
UTHealth & The University of Texas MD Anderson Cancer Center
Houston, Texas
Disclosure: I do not have any relevant financial / non-financial relationships with any proprietary interests.
MS

Monica Slavin

Professor
National Centre for Infections in Cancer, Peter MacCallum Cancer Centre
Melbourne, Victoria, Australia
Disclosure: I do not have any relevant financial / non-financial relationships with any proprietary interests.
YJ

Ying Jiang

Research Statistical Analyst
The University of Texas MD Anderson Cancer Center
Houston, Texas
Disclosure: I do not have any relevant financial / non-financial relationships with any proprietary interests.
Anne-Marie Chaftari

Associate Professor
MD Anderson UT
Houston, Texas
Disclosure: I do not have any relevant financial / non-financial relationships with any proprietary interests.
IR

Issam I. Raad

Professor
MD Anderson UT
Houston, Texas
Disclosure: Citius (Other Financial or Material Support, Ownership interest)Cook Medical (Grant/Research Support)Inventive Protocol (Other Financial or Material Support, Ownership interest)Novel Anti-Infective Technologies (Shareholder, Other Financial or Material Support, Ownership interest)

Background: Our objective was to describe the clinical course, risk factors and outcomes of patients infected with COVID-19 around the globe comparing cancer to non-cancer patients.

Methods: We conducted a retrospective cohort study of COVID-19 confirmed cases through an international multicenter collaboration including 17 centers around the world including the United States of America, Brazil, Europe, Far East, Middle East and Australia from January to date. We evaluated the patients’ clinical characteristics, clinical course of the disease, hospitalization and outcome. Death was considered to be COVID-associated if it occurred within 30 days from the time of diagnosis.

Results: Preliminary data on 571 patients included 186 cancer patients and 385 non-cancer patients.
Cancer patients were more likely to have COPD and received steroids but were less likely to have COVID-related symptoms compared to non-cancer patients (84% vs 97%, p< 0.0001). The rate of pneumonia with hypoxia, non-invasive ventilation and mechanical ventilation were similar in both groups. Despite the fact that hospital admissions were significantly higher in non-cancer patients (70% vs 56%, p< 0.001), promising antiviral and immune-related therapy including remdesivir, convalescent plasma and immunomodulators were more commonly used in cancer patients compared to non-cancer patients (P=0.04). Cancer patients had a higher COVID-associated mortality rate compared to non-cancer patients (20% vs 11%, p=0.006).

Conclusion: Despite the fact that cancer patients received more frequent antiviral and immune-related therapy, the mortality rate among cancer patients was significantly higher than non-cancer patients.